Early Phase 1 Parkinson's Disease Trial, Recruiting NCT06032026 Sponsor: University of Pennsylvania Condition: Parkinson's Disease
Back to Parkinsons Disease

Early Phase 1 Parkinson's Disease Trial, Recruiting

NCT06032026
Recruiting Early Phase 1

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • You have been clinically diagnosed with Multiple System Atrophy (MSA), Parkinson's Disease (PD), Progressive Supranuclear Palsy (PSP), or you are a healthy volunteer with no such diagnosis
  • You are a man or woman between the ages of 40 and 80
  • You are willing to sign a consent form agreeing to take part — or, if you are unable to sign for yourself, you have a trusted person (like a family member) who can be present to help with consent and accompany you to visits
  • You are willing to consider agreeing to donate your brain after death, though this is optional and not required to participate
  • Your diagnosis has been confirmed through a specialist review process (confirm with trial site)

Who may not be able to join:

  • Women who are currently pregnant or breastfeeding
  • People with a form of Parkinson's-like condition other than PD, PSP, or MSA
  • People with a major psychiatric condition such as schizophrenia or bipolar disorder (note: major depression is allowed)
  • People with a significant history of alcohol or drug abuse or dependence
  • People who are unable to tolerate brain/body scans, having a small tube placed in a vein or artery, or having blood drawn
  • People who cannot have an MRI scan, for example due to having certain metal implants in their body
  • People with PSP or MSA who have previously had a brain scan or spinal fluid test that showed signs of Alzheimer's-related protein buildup
  • People with any other medical condition that a doctor feels could make participation unsafe or difficult (confirm with trial site)

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 23 July 2026
Early Phase 1 studies are small, early exploratory studies that come before the main Phase 1 to 3 testing, so a standard phase success rate does not apply.

Contact this trial

Principal Investigator: Ilya Nasrallah, MD, University of Pennsylvania

Phone: 215-662-3041

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Early Phase 1
Registry
ClinicalTrials.gov
Start date
20 July 2023
Est. completion
31 July 2028

Where this trial is recruiting

🇺🇸 United States

Primary endpoints

Organ biodistribution; PET uptake of tracer

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 23 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov